Order Article Reprints

Tsakonas G, Specht L, Kristensen CA, Moreno MHC, Haugen Cange H, Soderstrom K, Friesland S. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). Cancers. 2020; 12(11):3110. https://doi.org/10.3390/cancers12113110

Tsakonas, Georgios, Lena Specht, Claus Andrup Kristensen, Maria Herlestam Calero Moreno, Hedda Haugen Cange, Karin Soderstrom, and Signe Friesland. 2020. "Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)" Cancers 12, no. 11: 3110. https://doi.org/10.3390/cancers12113110

Tsakonas, G., Specht, L., Kristensen, C. A., Moreno, M. H. C., Haugen Cange, H., Soderstrom, K., & Friesland, S. (2020). Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). Cancers, 12(11), 3110. https://doi.org/10.3390/cancers12113110